Robert J Flanagan
CIK 1251512 · last filed 2026-07-02
Robert J Flanagan is a corporate insider who has filed 50 SEC Form 4 insider transactions across 4 companies since 2007. The most recent filing, for WPC, was dated Jul 2, 2026. Across all open-market trades the lifetime net is −$12.6M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.5M across reported positions. 12 SEC filings were submitted jointly with W. P. Carey Inc.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
SGNT price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
58TH FL
NEW YORK, NY 10001
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| WPC | Director | 22,756 | $65.14 | $1.48M | $82.3K | 11 | 2026-07-02 |
| Sagent Pharmaceuticals, Inc. (SGNT) Delisted | Director | 13,970 | — | — | -$13.73M | 26 | 2016-02-25 |
| MARTEK BIOSCIENCES CORP (MATK) Delisted | Director | 0 | — | — | $0 | 7 | 2011-02-25 |
| Castle Brands Inc (ROX) Delisted | Director | 638,287 | — | — | $1.00M | 4 | 2008-09-25 |
Recent Filings
50 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-02 | WPC | Grant (A) | +2,824 | $0 | EDGAR |
| 2025-07-02 | WPC | Grant (A) | +2,778 | $0 | EDGAR |
| 2024-07-01 | WPC | Grant (A) | +3,203 | $0 | EDGAR |
| 2023-07-05 | WPC | Grant (A) | +2,553 | $0 | EDGAR |
| 2022-07-06 | WPC | Grant (A) | +1,919 | $0 | EDGAR |
| 2021-07-06 | WPC | Grant (A) | +2,141 | $0 | EDGAR |
| 2020-07-06 | WPC | Grant (A) | +2,180 | $0 | EDGAR |
| 2020-03-05 | WPC | Buy (P) | +1,000 | $82.3K | EDGAR |
| 2019-07-02 | WPC | Grant (A) | +1,867 | $0 | EDGAR |
| 2018-07-03 | WPC | Grant (A) | +1,523 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.